- Home
- CBRE vs WAT Comparison
CBRE vs WAT Comparison
Compare CBRE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | WAT |
|---|---|---|
| Founded | 1906 | 1958 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 33.5B |
| IPO Year | 2001 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CBRE | WAT |
|---|---|---|
| Price | $149.01 | $423.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $177.86 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 1.3M | 809.8K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.61 | 0.47 |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $40,550,000,000.00 | N/A |
| Revenue This Year | $14.31 | $104.66 |
| Revenue Next Year | $9.06 | $10.40 |
| P/E Ratio | $84.95 | ★ N/A |
| Revenue Growth | ★ 13.37 | N/A |
| 52 Week Low | $121.69 | $282.77 |
| 52 Week High | $174.27 | $421.74 |
Technical Indicators
Market Signals| Indicator | CBRE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 67.13 |
| Support Level | $148.76 | $372.18 |
| Resistance Level | $155.74 | N/A |
| Average True Range (ATR) | 3.81 | 10.95 |
| MACD | -0.30 | 0.19 |
| Stochastic Oscillator | 56.43 | 100.00 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.
About WAT Waters Corporation
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.